Cardiome Pharma (CRME) Misses Q4 EPS by 18c

Cardiome Pharma (NASDAQ: CRME) reported Q4 EPS of ($0.37), $0.18 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $7.74 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c